Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 1;139(4):481-489.
doi: 10.1097/AOG.0000000000004695. Epub 2022 Jan 5.

Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination: A U.S. Cohort

Alison Edelman  1 , Emily R Boniface, Eleonora Benhar, Leo Han, Kristen A Matteson, Carlotta Favaro, Jack T Pearson, Blair G Darney
Affiliations

Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination: A U.S. Cohort

Alison Edelman et al. Obstet Gynecol. .

Abstract

Objective: To assess whether coronavirus disease 2019 (COVID-19) vaccination is associated with changes in cycle or menses length in those receiving vaccination as compared with an unvaccinated cohort.

Methods: We analyzed prospectively tracked menstrual cycle data using the application "Natural Cycles." We included U.S. residents aged 18-45 years with normal cycle lengths (24-38 days) for three consecutive cycles before the first vaccine dose followed by vaccine-dose cycles (cycles 4-6) or, if unvaccinated, six cycles over a similar time period. We calculated the mean within-individual change in cycle and menses length (three prevaccine cycles vs first- and second-dose cycles in the vaccinated cohort, and the first three cycles vs cycles four and five in the unvaccinated cohort). We used mixed-effects models to estimate the adjusted difference in change in cycle and menses length between the vaccinated and unvaccinated cohorts.

Results: We included 3,959 individuals (vaccinated 2,403; unvaccinated 1,556). Most of the vaccinated cohort received the Pfizer-BioNTech vaccine (55%) (Moderna 35%, Johnson & Johnson/Janssen 7%). Overall, COVID-19 vaccine was associated with a less than 1-day change in cycle length for both vaccine-dose cycles compared with prevaccine cycles (first dose 0.71 day-increase, 98.75% CI 0.47-0.94; second dose 0.91, 98.75% CI 0.63-1.19); unvaccinated individuals saw no significant change compared with three baseline cycles (cycle four 0.07, 98.75% CI -0.22 to 0.35; cycle five 0.12, 98.75% CI -0.15 to 0.39). In adjusted models, the difference in change in cycle length between the vaccinated and unvaccinated cohorts was less than 1 day for both doses (difference in change: first dose 0.64 days, 98.75% CI 0.27-1.01; second dose 0.79 days, 98.75% CI 0.40-1.18). Change in menses length was not associated with vaccination.

Conclusion: Coronavirus disease 2019 (COVID-19) vaccination is associated with a small change in cycle length but not menses length.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure Alison Edelman reports honoraria and travel reimbursement from ACOG, WHO, and Gynuity for committee activities and honoraria for peer review from the Karolinska Institute. Alison Edelman receives royalties from UpToDate, Inc. Oregon Health & Science University (OHSU) receives research funding from OHSU Foundation, Merck, HRA Pharma, and NIH for which Alison Edelman is the principal investigator. Blair G. Darney reports honoraria and travel reimbursement from ACOG and SFP for board, committee, and mentorship activities. OHSU receives research funding from Merck/Organon and OPA/DHHS for which Blair G. Darney is the principal investigator. OHSU receives research funding from OHSU foundation, the Bill & Melinda Gates Foundation, ABOG, ASRM and the NIH for which Leo Han is the principal investigator. Eleonora Benhar, Carlotta Favaro, and Jack T. Pearson are employees of Natural Cycles. Kristen A. Matteson reports honoraria and travel reimbursement from ABOG and travel reimbursement from ACOG. Women & Infants Hospital received funding from Myovant for consulting work done by Kristen A. Matteson on outcomes measures for heavy menstrual bleeding. Emily R. Boniface did not report any potential conflicts of interest.

Figures

Fig. 1.
Fig. 1.. STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) flow diagram. COVID-19, coronavirus disease 2019.
Edelman. COVID-19 Vaccine and Menstrual Health Outcomes. Obstet Gynecol 2022.
Fig. 2.
Fig. 2.. A. Overlayed histograms of the change in cycle length (days) between the three prevaccination cycle average and the vaccination cycle for first dose (left) or second dose (right). Histograms for unvaccinated individuals are shown in red, vaccinated individuals are shown in blue, and overlapping distributions are shown in purple. B. Adjusted marginal means for cycle length (days) for the three prevaccination cycle average and the vaccination cycle first dose (left) or second dose (right). Estimates are from mixed-effects models with random intercepts and random slopes at the user level, an interaction between vaccination status and prevaccination and postvaccination timing, and adjusted for age, race, body mass index, educational attainment, parity, and relationship status. Unvaccinated individuals are shown in red, and vaccinated individuals are shown in blue; error bars represent 98.75% CIs.
Edelman. COVID-19 Vaccine and Menstrual Health Outcomes. Obstet Gynecol 2022.
See this image and copyright information in PMC

Comment in

References

    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. New Engl J Med 2020;383:2603–15. doi: 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. . The Advisory Committee on Immunization Practices' interim recommendation for use of Moderna COVID-19 vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep 2021;69:1653–6. doi: 10.15585/mmwr.mm695152e1 - DOI - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. New Engl J Med 2021;384:2187–201. doi: 10.1056/NEJMoa2101544 - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Engl J Med 2021;384:403–16. doi: 10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. NOT-HD-21-035: notice of special interest (NOSI) to encourage administrative supplement applications to investigate COVID-19 vaccination and menstruation (admin supp clinical trial optional). Accessed June 12, 2021. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-21-035.html

Publication types

Substances